Leerink Partners Raises Price Target on Regeneron (REGN) Following 1Q Report
Tweet Send to a Friend
Leerink Partners reiterated an Outperform rating on Regeneron Pharma (NASDAQ: REGN), and raised the price target to $530.00 (from $523.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
